Qurient Co

Qurient Co Liabilities

The The Liabilities of Qurient Co (115180.KQ) as of Nov 17, 2026 is 22.80 B KRW. In the previous year, The Liabilities was 7.97 B KRW — a change of 185.93% (higher).

Liabilities

22.80 BKRW

YoY

185.93%

Last updated:

In 2025, Qurient Co's total liabilities amounted to 22.80 B KRW, a 185.93% difference from the 7.97 B KRW total liabilities in the previous year.

The Qurient Co Liabilities history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Liabilities
Date
Liabilities
Jan 1, 2018
3.79 B KRW
Jan 1, 2019
3.14 B KRW
Jan 1, 2020
4.24 B KRW
Jan 1, 2021
3.55 B KRW
Jan 1, 2022
3.28 B KRW
Jan 1, 2023
5.88 B KRW
Jan 1, 2024
7.97 B KRW
Jan 1, 2025
22.80 B KRW
The Qurient Co Liabilities history
YEARLiabilitiesYoY
22.80 BKRW+185.93%
7.97 BKRW+35.53%
5.88 BKRW+79.65%
3.28 BKRW-7.61%
3.55 BKRW-16.46%
4.24 BKRW+35.36%
3.14 BKRW-17.30%
3.79 BKRW+230.89%
1.15 BKRW-39.40%
1.89 BKRW+96.17%
963.76 MKRW-97.09%
33.11 BKRW—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Qurient Co Stock analysis

What does Qurient Co do? Qurient Co., Ltd. develops novel therapeutics with two main program phases. The development phase includes Q203 for drug-resistant tuberculosis, Q301 for atopic dermatitis, and Q701 for drug-resistant cancer and anti-cancer immunotherapy. The research phase focuses on five lipoxygenase (5LO) inhibitor asthma medicines and a cyclin dependent kinase 7 (CDK7) inhibitor cancer drug. The company generates revenue through these therapeutic programs, targeting pharmaceutical companies and healthcare providers seeking innovative treatments for resistant diseases and chronic conditions. Qurient's products are developed for specific medical needs, with Q203 addressing tuberculosis that resists standard drugs, Q301 treating skin inflammation conditions, and Q701 enhancing cancer immunotherapy. The research phase programs aim to advance asthma and cancer treatments through novel inhibitors. Pharmaceutical companies and healthcare providers purchase these therapies to address unmet medical needs in their markets. The company's revenue streams come from the development and potential commercialization of Q203, Q301, Q701, and the research phase programs. These programs target segments including tuberculosis treatment, dermatology, oncology, and respiratory diseases. Pharmaceutical firms and healthcare institutions are the primary buyers of Qurient's therapeutic solutions for drug-resistant conditions and advanced treatment options. Qurient Co is one of the most popular companies on Eulerpool.

Liabilities Details

Assessing Qurient Co's Liabilities

Qurient Co's liabilities constitute the company's financial obligations and debts owed to external parties and stakeholders. They are categorized into current liabilities, due within a year, and long-term liabilities, which are due over a longer period. A detailed assessment of these liabilities is crucial for evaluating Qurient Co's financial stability, operational efficiency, and long-term viability.

Year-to-Year Comparison

By comparing Qurient Co's liabilities year-over-year, investors can identify trends, shifts, and anomalies in the company’s financial positioning. A decrease in total liabilities often signals financial strengthening, while an increase might indicate enhanced investments, acquisitions, or potential financial strain.

Impact on Investments

Qurient Co's total liabilities play a significant role in determining the company's leverage and risk profile. Investors and analysts examine this aspect meticulously to ascertain the firm’s ability to meet its financial obligations, which influences investment attractiveness and credit ratings.

Interpreting Liability Fluctuations

Shifts in Qurient Co’s liability structure indicate changes in its financial management and strategy. A reduction in liabilities reflects efficient financial management or debt payoffs, while an increase may suggest expansion, acquisition activities, or accruing operational expenses, each carrying distinct implications for investors.

Frequently Asked Questions about Qurient Co stock

The Liabilities of Qurient Co is 22.80 B KRW in 2025.

The Liabilities of Qurient Co changed from 7.97 B KRW to 22.80 B KRW, representing a 185.93% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of The Liabilities Qurient Co since 2006 – with annual values, charts, and detailed analysis.

The Liabilities's KRW is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track The Liabilities's Qurient Co historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Balance Sheet — Qurient Co

All Key Metrics — Qurient Co